Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial - 24/12/11
, Bruce G. Bender, PhD b, Frederick S. Wamboldt, MD b, Stanley J. Szefler, MD b, N. Franklin Adkinson, MD c, Robert S. Zeiger, MD, PhD d, Robert A. Wise, MD c, Andrew L. Bilderback, MS c, Cynthia S. Rand, PhD cAdherence Ancillary Study Group
Corresponding author: Jerry A. Krishnan, MD, PhD, Section of Pulmonary, Critical Care, Sleep, and Allergy, Department of Medicine, University of Illinois at Chicago, 840 S Wood St, M/C 719, Chicago, IL 60612.Abstract |
Background |
Information comparing subjective and objective measurements of adherence to study medications and the effects of adherence on treatment-related differences in asthma clinical trials are limited.
Objective |
We sought to compare subjective and objective measurements of children’s adherence to inhaled corticosteroids or placebo and to determine whether adherence to study medications modified treatment-related differences in outcomes.
Methods |
In an ancillary study conducted in 3 of 8 Childhood Asthma Management Program Clinical Centers, adherence was assessed by using self-reported and objective data in 5- to 12-year-old children with mild or moderate asthma who were randomly assigned to 200 μg of inhaled budesonide twice per day (n = 84) or placebo (n = 56) for 4 years. The κ statistic was used to evaluate agreement between self-reported adherence (daily diary cards) and objectively measured adherence (number of doses left in study inhalers). Multivariable analyses were used to determine whether adherence to study treatment modified treatment-related differences in outcomes.
Results |
Adherence of less than 80% was seen in 75% of 140 children when adherence was measured objectively but only in 6% of children when measured by means of self-report. There was poor agreement between objective and subjective measurements of adherence of at least 80% (κ = 0.00; 95% CI, −0.05 to 0.04); self-reported adherence over the 4-year period generally overestimated objectively measured adherence (93.6% vs 60.8%, P < .0001). There was little evidence to indicate that adherence modified treatment-related differences in outcomes.
Conclusion |
Researchers should use objective rather than self-reported adherence data to identify clinical trial participants with low levels of adherence to study treatment.
El texto completo de este artículo está disponible en PDF.Key words : Asthma, adherence, compliance, children, lung growth, inhaled corticosteroids, budesonide, clinical trial
Abbreviations used : adherence4yrs, CAMP, FVC, ICS
Esquema
| The Childhood Asthma Management Program is supported by the National Heart, Lung, and Blood Institute (NHLBI; contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052). The adherence ancillary study was supported by the NHLBI (HL048999). |
|
| Disclosure of potential conflict of interest: J. A. Krishnan receives research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). S. J. Szefler has consultant arrangements with GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and receives research support from the NIH/NHLBI’s Childhood Asthma Management Program, the NHLBI’s Childhood Asthma Research and Education, the NIH/NHLBI’s Asthma Clinical Research Network, the NIH/National Institute of Allergy and Infectious Diseases’s Inner City Asthma Consortium, GlaxoSmithKline, National Jewish Health/NHLBI Asthma Net, and the National Institute of Environmental Health Sciences/US Environmental Protection Agency’s Children’s Environmental Health Center grant. R. S. Zeiger has consultant arrangements with AstraZeneca, Aerocrine, Genentech, Merck and Co, Schering-Plough, MedImmune, Sunovion, and Centocor and receives research support from Aerocrine, Genentech, Merck and Co, and GlaxoSmithKline. R. A. Wise has consultant arrangements with AstraZeneca. C. S. Rand is an advisor for the Merck Foundation/MCAN and has consultant arrangements with TEVA. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 129 - N° 1
P. 112-118 - janvier 2012 Regresar al número
Artículo precedente
- Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma
- Aarti Shikotra, David F. Choy, Chandra M. Ohri, Emma Doran, Claire Butler, Beverley Hargadon, Maria Shelley, Alexander R. Abbas, Cary D. Austin, Janet Jackman, Lawren C. Wu, Liam G. Heaney, Joseph R. Arron, Peter Bradding
- Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps
- Sarah Peterson, Julie A. Poposki, Deepti R. Nagarkar, Regina T. Chustz, Anju T. Peters, Lydia A. Suh, Roderick Carter, James Norton, Kathleen E. Harris, Leslie C. Grammer, Bruce K. Tan, Rakesh K. Chandra, David B. Conley, Robert C. Kern, Robert P. Schleimer, Atsushi Kato
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?